Table 3.
Clinical and pathological characteristics of 119 patients with breast cancer in the present validation cohort
| Clinical and pathological characteristics | Tis/Stage I (%) N=34 | Stage II (%) N=22 | Stage III (%) N=20 | Stage IV (%) N=43 | P value | |
|---|---|---|---|---|---|---|
| Age (years) | 0.870 | |||||
| < 50 | 17 (50.0) | 9 (40.9) | 10 (50.0) | 22 (51.2) | ||
| ≥ 50 | 17 (50.0) | 13 (59.1) | 10 (50.0) | 21 (48.8) | ||
| T | < 0.001 | |||||
| Tis | 5 (14.7) | 0 | 0 | 0 | ||
| T1 | 29 (85.3) | 4 (18.2) | 0 | 10 (23.3) | ||
| T2 | 0 | 17 (77.3) | 1 (5.0) | 25 (58.1) | ||
| T3 | 0 | 1 (4.5) | 13 (65.0) | 3 (7) | ||
| T4 | 0 | 0 | 6 (30.0) | 5 (11.6) | ||
| N | < 0.001 | |||||
| Negative | 34 (100.0) | 2 (9.1) | 1 (5.0) | 12 (27.9) | ||
| Positive | 0 | 20 (90.9) | 19 (95.0) | 31 (72.1) | ||
| M | < 0.001 | |||||
| Negative | 34 (100.0) | 22 (100.0) | 20(100.0) | 0 | ||
| Positive | 0 | 0 | 0 | 43(100.0) | ||
| ER | < 0.001 | |||||
| Negative | 6 (17.6) | 5 (22.7) | 8 (40.0) | 33 (76.7) | ||
| Positive | 28 (82.4) | 17 (77.3) | 12 (60.0) | 10 (23.3) | ||
| PR | < 0.001 | |||||
| Negative | 6 (17.6) | 8 (36.4) | 9 (45.0) | 35 (81.4) | ||
| Positive | 28 (82.4) | 14 (63.6) | 11 (55.0) | 8 (18.6) | ||
| HER2 | 0.002 | |||||
| Negative | 31 (91.2) | 13 (59.1) | 15 (75.0) | 40 (93.0) | ||
| Positive | 3 (8.8) | 9 (40.9) | 5 (25.0) | 3 (7.0) | ||
| Ki67 | 0.002 | |||||
| ≤ 20% | 16 (47.1) | 3 (13.6) | 4 (20.0) | 5 (11.6) | ||
| > 20% | 18 (52.9) | 19 (86.4) | 16 (80.0) | 38 (88.4) | ||
| Immunohistochemical type | < 0.001 | |||||
| Luminal | 27 (79.4) | 10 (45.5) | 10 (50.0) | 9 (20.9) | ||
| HER2 positive | 3 (8.8) | 9 (40.9) | 5 (25.0) | 3 (7.0) | ||
| TNBC | 4 (11.8) | 3 (13.6) | 5 (25.0) | 31 (72.1) | ||